BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19343218)

  • 1. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.
    Jern P; Russell RA; Pathak VK; Coffin JM
    PLoS Pathog; 2009 Apr; 5(4):e1000367. PubMed ID: 19343218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.
    Ulenga NK; Sarr AD; Hamel D; Sankale JL; Mboup S; Kanki PJ
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1285-90. PubMed ID: 18851679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.
    Armitage AE; Deforche K; Chang CH; Wee E; Kramer B; Welch JJ; Gerstoft J; Fugger L; McMichael A; Rambaut A; Iversen AK
    PLoS Genet; 2012; 8(3):e1002550. PubMed ID: 22457633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.
    Miller JH; Presnyak V; Smith HC
    Retrovirology; 2007 Nov; 4():81. PubMed ID: 18036235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.
    Zhang L; Saadatmand J; Li X; Guo F; Niu M; Jiang J; Kleiman L; Cen S
    Virology; 2008 Jan; 370(1):113-21. PubMed ID: 17916373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of the two cytidine deaminase domains in APOBEC3G.
    Li X; Ma J; Zhang Q; Zhou J; Yin X; Zhai C; You X; Yu L; Guo F; Zhao L; Li Z; Zeng Y; Cen S
    Virology; 2011 Jun; 414(2):130-6. PubMed ID: 21489586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.
    Armitage AE; Katzourakis A; de Oliveira T; Welch JJ; Belshaw R; Bishop KN; Kramer B; McMichael AJ; Rambaut A; Iversen AK
    J Virol; 2008 Sep; 82(17):8743-61. PubMed ID: 18562517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.
    Sadler HA; Stenglein MD; Harris RS; Mansky LM
    J Virol; 2010 Jul; 84(14):7396-404. PubMed ID: 20463080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation.
    Ma L; Zhang Z; Liu Z; Pan Q; Wang J; Li X; Guo F; Liang C; Hu L; Zhou J; Cen S
    Sci Rep; 2018 May; 8(1):8067. PubMed ID: 29795228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Escape from Small-Molecule Antagonism of Vif.
    Sharkey M; Sharova N; Mohammed I; Huff SE; Kummetha IR; Singh G; Rana TM; Stevenson M
    mBio; 2019 Feb; 10(1):. PubMed ID: 30808702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
    Schröfelbauer B; Senger T; Manning G; Landau NR
    J Virol; 2006 Jun; 80(12):5984-91. PubMed ID: 16731937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
    Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
    Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation.
    Mercenne G; Bernacchi S; Richer D; Bec G; Henriet S; Paillart JC; Marquet R
    Nucleic Acids Res; 2010 Jan; 38(2):633-46. PubMed ID: 19910370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
    Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
    J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
    Pillai SK; Wong JK; Barbour JD
    Retrovirology; 2008 Mar; 5():26. PubMed ID: 18339206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.